1. The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential
- Author
-
Jingwen Xiong, Xuancheng Zhou, Lanqian Su, Lai Jiang, Ziwei Ming, Can Pang, Claire Fuller, Ke Xu, Hao Chi, and Xiaomei Zheng
- Subjects
GBM ,TAM ,Reprogramming ,Immunotherapy ,Phenotypic transition ,TME ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Gliomas are the most common primary malignant tumours of the central nervous system (CNS), which are highly aggressive, with increasing morbidity and mortality rates year after year, posing a serious threat to the quality and expected survival time of patients. The treatment of gliomas is a major challenge in the field of neuro-oncology, especially high-grade gliomas such as glioblastomas (GBMs). Despite considerable progress in recent years in the study of the molecular and cellular mechanisms of GBMs, their prognosis remains bleak. Tumour-associated macrophages (TAMs) account for up to 50% of GBMs, and they are a highly heterogeneous cell population whose role cannot be ignored. Here, we focus on reviewing the contribution of classically activated M1-phenotype TAMs and alternatively activated M2-phenotype TAMs to GBMs, and exploring the research progress in reprogramming M1 TAMs into M2 TAMs.
- Published
- 2024
- Full Text
- View/download PDF